The stock of Carisma Therapeutics Inc (CARM) has seen a -6.47% decrease in the past week, with a -28.83% drop in the past month, and a -55.59% decrease in the past quarter. The volatility ratio for the week is 7.44%, and the volatility levels for the past 30 days are at 6.14% for CARM. The simple moving average for the past 20 days is -7.21% for CARM’s stock, with a -70.80% simple moving average for the past 200 days.
Is It Worth Investing in Carisma Therapeutics Inc (NASDAQ: CARM) Right Now?
CARM has 36-month beta value of 1.69. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CARM is 21.12M, and currently, short sellers hold a 3.98% ratio of that float. The average trading volume of CARM on June 04, 2025 was 440.35K shares.
CARM) stock’s latest price update
The stock price of Carisma Therapeutics Inc (NASDAQ: CARM) has dropped by -11.15 compared to previous close of 0.20. Despite this, the company has seen a fall of -6.47% in its stock price over the last five trading days. prnewswire.com reported 2025-03-31 that Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA, March 31, 2025 /PRNewswire/ — Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”) today announced that its Board of Directors has approved a revised operating plan focused on evaluating strategic alternatives while reducing operational cash burn. The Company’s goal is to maximize the value of its assets, including its liver fibrosis and oncology development programs, its macrophage and monocyte engineering platform and the CAR-M platform and to realize value from the potential future milestone and royalty payments under Carisma’s agreement with Moderna.
Analysts’ Opinion of CARM
Many brokerage firms have already submitted their reports for CARM stocks, with Robert W. Baird repeating the rating for CARM by listing it as a “Neutral.” The predicted price for CARM in the upcoming period, according to Robert W. Baird is $1 based on the research report published on December 12, 2024 of the previous year 2024.
BTIG Research gave a rating of “Buy” to CARM, setting the target price at $6 in the report published on April 11th of the previous year.
CARM Trading at -18.95% from the 50-Day Moving Average
After a stumble in the market that brought CARM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.65% of loss for the given period.
Stock Fundamentals for CARM
Current profitability levels for the company are sitting at:
- -2.63 for the present operating margin
- 0.94 for the gross margin
The net margin for Carisma Therapeutics Inc stands at -3.13. The total capital return value is set at -7.75. Equity return is now at value -362.79, with -113.13 for asset returns.
Based on Carisma Therapeutics Inc (CARM), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -20.46. The debt to equity ratio resting at -0.06. The interest coverage ratio of the stock is -83.99.
Currently, EBITDA for the company is -57.12 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.34.
Conclusion
To put it simply, Carisma Therapeutics Inc (CARM) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
